Adaptive Biotechnologies’ stock rose following new NCCN multiple myeloma guidelines recommending baseline clonotype identification or aspirate storage at diagnosis to facilitate minimal residual disease (MRD) testing via NGS. Separately, the Association for Molecular Pathology published best practice guidelines to standardize homologous recombination deficiency (HRD) diagnostics critical for personalized cancer therapies. These developments reflect ongoing efforts to enhance molecular diagnostic accuracy, optimize clinical workflows, and improve treatment stratification for oncologic patients across diverse healthcare settings.